Fig. 1 · Structure

Documents & Downloads

G007-LK

Cat. No. A15528 CAS 1380672-07-0

TNKS inhibitor

G007-LK displays high selectivity toward tankyrases 1 and 2 with biochemical IC50 values of 46 nM and 25 nM, respectively, and a cellular IC50 value of 50 nM combined with an excellent pharmacokinetic profile in mice,

In Stock

Publications for G007-LK

1 publication citing this product

  1. Dominic B. Bernkopf, .et al. , Nat Commun, 2019, 10:4251 PMID: 31534175

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

G007-LK produced AXIN stabilization and model-dependent suppression of Wnt/β-catenin signaling in tumor cells. In a five-cell-line panel, a 72-hour Wnt reporter assay gave an IC50 of 510 nM in COLO 320DM cells, whereas the other four lines did not reach 50% reporter inhibition at concentrations up to 1000 nM. These cellular reporter values are distinct from enzyme potency and growth-inhibition endpoints. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
TNKS2 IC50 25 nM
TNKS1 IC50 46 nM

Cellular Effect

Cell Line Activity Value Description Reference
COLO 320DM GI50 0.43 μM Antiproliferative activity against human COLO320DM cells assessed inhibition of cell growth measured after 5 days by MTT assay [PMID: 32202790]
COLO 320DM GI50 0.43 μM Antiproliferative activity against human COLO320DM cells assessed inhibition of cell growth measured after 5 days by MTT assay [PMID: 30883102]
COLO 320DM GI50 1.5 μM Antiproliferative activity against human COLO320DM cells assessed as inhibition of cell growth measured after 4 days by CellTiter-Glo assay [PMID: 32202790]
COLO 320DM GI50 1.5 μM Antiproliferative activity against human COLO320DM cells assessed as inhibition of cell growth measured after 4 days by CellTiter-Glo assay [PMID: 30883102]
HEK293 IC50 0.05 μM Inhibition of TNKS1/2 in HEK293 cells assessed as inhibition of Wnt/beta-casein pathway after 24 hrs by luciferase reporter gene assay [PMID: 23473363]
HEK293 IC50 4.5 nM Inhibition of TNKS/TNKS2 (unknown origin) expressed in HEK293 cells assessed as reduction in Wnt-signaling measured after 24 hrs by TCF-luciferase reporter gene assay [PMID: 32202790]
HEK293 IC50 4.5 nM Inhibition of TNKS/TNKS2 (unknown origin) expressed in HEK293 cells assessed as reduction in Wnt-signaling measured after 24 hrs by TCF-luciferase reporter gene assay [PMID: 30883102]
RKO GI50 8.9 μM Antiproliferative activity against human RKO cells assessed inhibition of cell growth measured after 5 days by MTT assay [PMID: 32202790]
RKO GI50 8.9 μM Antiproliferative activity against human RKO cells assessed inhibition of cell growth measured after 5 days by MTT assay [PMID: 30883102]
Sf9 IC50 > 100000 nM Inhibition of human recombinant N-terminal GST-tagged PARP2 (2 to 583 residues) expressed in baculovirus infected Sf9 cells assessed as reduction in auto-PARylation using histone as substrate measured after 45 mins in presence of biotinylated-NAD+ by ELIS [PMID: 32202790]
Sf9 IC50 > 100000 nM Inhibition of human recombinant N-terminal GST-tagged PARP2 (2 to 583 residues) expressed in baculovirus infected Sf9 cells assessed as reduction in auto-PARylation using histone as substrate measured after 45 mins in presence of biotinylated-NAD+ by ELIS [PMID: 30883102]

11 records · Scroll to view more

G007-LK Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of G007-LK from 3 published references. In vitro models include COLO 320DM, UO-31, OVCAR-4, ABC-1 and RKO tumor cell lines.

G007-LK In Vitro Studies

In a screen of 537 human tumor cell lines, 87 (16%) had GI25 values below 1 μM G007-LK. Follow-up MTS assays gave GI50 values of 54–844 nM in four selected sensitive lines, while RKO had a GI50 above 1000 nM. Potencies differed between the initial screen and validation assays, supporting an assay- and model-specific interpretation. [1]

In SW480 cells, 50 nM G007-LK overnight reduced β-catenin-dependent reporter activity by about 40%. Combining it with expression of an AXIN2-derived P182–195 peptide increased the reported inhibition to about 75%; peptide expression alone also inhibited the reporter. This reporter experiment supports a combination effect, without establishing formal pharmacological synergy or a G007-LK growth effect. [2]

Tumor-cell screening and selected-cell validation

Cell-based study · 537 human tumor cell lines from 29 tissue origins; follow-up COLO 320DM, UO-31, OVCAR-4, ABC-1 and negative-control RKO [1]

A minority of screened lines met the GI25 threshold. Selected sensitive lines were validated by MTS assays, with RKO serving as an insensitive comparator. Initial screen and follow-up GI50 values differ and should remain assay-specific.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Lines with GI25 <1 μM G007-LKGI25 hit count 87 of 537 (16%)[1]
Selected-cell MTS growth inhibitionGI50 COLO 320DM: 844 nM; UO-31: 242 nM; OVCAR-4: 54 nM; ABC-1: 145 nM; RKO: >1000 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Various concentrations; GI25 threshold <1 μM; selected-cell MTS dose responses shown in Fig. 1C.
Exposure duration
Initial NCI-60 panel: 48 h; Genentech panel: 72 h. MTS validation: Fig. 1C states 4–8 days; shared Proliferation assays methods state 5–8 days.
Method
Initial screening: SRB (NCI-60) or CellTiter-Glo (Genentech); follow-up endpoint MTS absorbance at 492 nm, normalized to vehicle and time-zero values.
Vehicle
DMSO controls in initial screens; follow-up MTS: 0.01% DMSO.
Reported limits
Exact validation duration for each cell line is not specified in Fig. 1; figure and shared methods give overlapping but different ranges. These values are growth-inhibition endpoints, not biochemical IC50 values.
Methods and source locations

Compound reported in the paper: G007-LK; Compound label in the paper: G007-LK

Applies to the paper’s named G007-LK preparation and stated model/assay; does not validate a present supplier lot or another form.

Results, proliferation screen first two paragraphs; Fig. 1A–D; key resources and selected screening/treatment/MTS methods

Lines with GI25 <1 μM G007-LK: Two initial screening panels with different readouts and durations; author-reported aggregate. — Results, proliferation screen first paragraph; Fig. 1A; STAR Methods, Human tumor cell line anti-proliferative screens

Selected-cell MTS growth inhibition: Endpoint MTS; Fig. 1C: mean ± SD for one representative experiment of at least two repeated assays, each with six replicates. Values transcribed from the viewed Fig. 1D table, not estimated from bars. — Fig. 1C–D and caption; STAR Methods, Proliferation assays

AXIN stabilization and model-dependent Wnt reporter response

Cell-based study · COLO 320DM, UO-31, OVCAR-4, ABC-1 and RKO tumor cell lines [1]

G007-LK stabilized AXIN1 across this panel, while AXIN2 stabilization and β-catenin changes depended on cell type. Detectable dose-dependent reporter inhibition within the tested range was confined to COLO 320DM. This does not explain all growth responses in the selected cell lines.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
AXIN and β-catenin protein responsesQualitative immunoblot response AXIN1 stabilized in all five lines; AXIN2 stabilized in COLO 320DM and ABC-1. Nuclear β-catenin decreased in COLO 320DM at 24 h, with more modest reductions in OVCAR-4 and ABC-1 at 72 h.[1]
Wnt/β-catenin luciferase reporter suppressionCellular reporter IC50 / IC25 COLO 320DM: IC50 510 nM, IC25 100 nM; UO-31, OVCAR-4, ABC-1 and RKO: both >1000 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Immunoblots: 1 μM. Reporter: concentration-response assay; values in Fig. 3F.
Exposure duration
Immunoblots: 24 or 72 h; stable Wnt reporter concentration-response: 72 h.
Method
Cytoplasmic/nuclear immunoblots with actin and lamin B1 loading controls; Wnt-responsive luciferase normalized to Renilla. Baseline TOP/FOP controls shown separately in Fig. 3E.
Vehicle
0.01% DMSO
Reported limits
Biochemical target IC50, direct binding and a universal cellular potency are not measured by these readouts.
Methods and source locations

Compound reported in the paper: G007-LK; Compound label in the paper: G007-LK

Applies to the paper’s named G007-LK preparation and stated model/assay; does not validate a present supplier lot or another form.

Results, WNT/β-catenin subsection; Fig. 3D–F; key resources, treatment, immunoblot and reporter readout methods

AXIN and β-catenin protein responses: Representative blots from two or more independent experiments; actin and lamin B1 loading controls. No numerical fold change inferred. — Fig. 3D and caption; Results, G007-LK inhibits WNT/β-catenin signaling

Wnt/β-catenin luciferase reporter suppression: 72-h reporter assay relative to 0.01% DMSO; table values transcribed from viewed Fig. 3F. These are reporter endpoints, not growth GI50 or enzyme IC50. — Fig. 3E–F and caption; STAR Methods, Luciferase reporter assays (readout/normalization)

G007-LK and an AXIN2-derived peptide in a factorial reporter assay

Cell-based study · SW480 colorectal cancer cells transfected with a peptide-expression construct [2]

G007-LK alone and low-dose expression of the AXIN2-derived P182–195 peptide each reduced β-catenin-dependent reporter activity. Their combination produced a larger reduction in the same experiment. The peptide is an expressed construct here, not the separately tested synthetic cell-penetrating peptide.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
β-catenin-dependent transcriptionApproximate reporter inhibition About 40% inhibition by 50 nM G007-LK alone or 5 ng peptide vector alone; about 75% inhibition by the combination.[2]

Literature-Reported Treatment Conditions

Treatment concentration
G007-LK: 50 nM; peptide-expression vector: 5 ng per 12-well transfection.
Exposure duration
G007-LK overnight (Fig. 7m).
Method
TOP/FOP luciferase reporter with β-galactosidase normalization; untreated/no-peptide, peptide-only, G007-LK-only and combination conditions.
Co-treatment
G007-LK plus expressed P182–195 peptide; single-agent comparators included.
Reported limits
Drug vehicle not specified in the selected methods/caption. Overnight is the reported duration; no exact hour count inferred.
Methods and source locations

Compound reported in the paper: G007-LK; Compound label in the paper: G007-LK

Applies to the paper’s named G007-LK preparation and stated model/assay; does not validate a present supplier lot or another form.

Results, final paragraph before Discussion; Fig. 7a,m; Methods, Cell culture/transfection/small chemicals and Luciferase reporter assay

β-catenin-dependent transcription: Author-text approximations, consistent with viewed Fig. 7m. Caption reports mean ± SEM (n=3); shared reporter methods specify technical duplicates. No formal synergy model or proliferation endpoint claimed. — Results, final paragraph before Discussion; Fig. 7a,m and caption; Methods, Luciferase reporter assay

G007-LK In Vivo Studies

In seven-week-old male wild-type mice, dietary G007-LK reported at 400 μg/day for four weeks reduced tibial and lumbar vertebral trabecular bone volume by approximately 30% and 22%, respectively, and reduced tibial cortical thickness (n=4/group). Osteoclast number and surface increased, while serum TRAP5b, PINP and osteocalcin differences were not significant. The findings identify a bone-related limitation under this regimen. [3]

Dietary G007-LK reduces bone mass in male mice

Animal study · Seven-week-old wild-type male C57BL/6J mice; n=4/group [3]

Dietary G007-LK reduced trabecular bone volume in tibias and lumbar vertebrae and reduced tibial cortical thickness, with increased osteoclast number/surface. Serum bone-turnover markers did not show significant differences. This is an adverse bone finding under the tested regimen.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tibial/vertebral trabecular BV/TV and tibial cortical thicknessRelative reduction; micro-CT Tibial BV/TV decreased approximately 30%; lumbar vertebral BV/TV decreased approximately 22%; tibial cortical thickness significantly decreased (P<0.05 versus control).[3]
Osteoclast histomorphometry and serum turnover markersDirectional results / P values Osteoclast number and surface increased (P<0.05); serum TRAP5b P=0.139, PINP P=0.864, OCN P=0.954.[3]

Conditions shared by the study groups

Route
Oral, in diet
Frequency
Daily dietary administration
Treatment course
4 weeks / 28 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Dietary G007-LK
400 μg/day G007-LK as reported in section 2.10; no mg/kg conversion.
Control diet groupTibial and vertebral trabecular BV/TV decreased; cortical thickness decreased; osteoclast numbers and surface increased. Serum TRAP5b, PINP and OCN differences were not statistically significant.[3]
Dietary G007-LK
Model: Seven-week-old wild-type male C57BL/6J mice; n=4/group in Fig. 6.
Reported limits: Diet incorporation formulation and individual measured daily exposure are not specified in the selected methods; intake was monitored per cage. No injected dose or solution vehicle inferred.
Methods and source locations

Compound reported in the paper: G007-LK; Compound label in the paper: G007-LK

Applies to the paper’s named G007-LK preparation and stated model/assay; does not validate a present supplier lot or another form.

Sections 2.1–2.2, 2.10–2.14 and 3.6; Figs. 6–7 and captions

Tibial/vertebral trabecular BV/TV and tibial cortical thickness: Percent reductions are approximate values from original Results prose, not digitized graphs. Fig. 6: n=4/group, mean ± SD; section 2.14 specifies two-tailed unpaired Student t-test for two groups. — Section 3.6; Fig. 6B,D,F and caption

Osteoclast histomorphometry and serum turnover markers: TRAP histology and serum ELISA; mean ± SD. Exact serum P values read from viewed Fig. 7D–F; no significant increase in serum TRAP5b claimed. — Section 3.6; Fig. 7B–F and caption; sections 2.12–2.14

Dietary G007-LK · Sections 2.1–2.2, 2.10–2.14 and 3.6; Figs. 6–7 and captions

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1380672-07-0
Applications TNKS inhibitor
Formula C25H16ClN7O3S
Molecular Weight 529.96
SMILES
CS(=O)(=O)C1=CN=C(C=C1)C2=NN=C(N2C3=CC=CC=C3Cl)C=CC4=NN=C(O4)C5=CC=C(C=C5)C#N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 98 mg/mL (184.92 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

G007-LK Research References

  1. [1] Mygland L, Brinch SA, Strand MF, et al. Identification of response signatures for tankyrase inhibitor treatment in tumor cell lines. iScience (2021). PMID: 34337362 DOI: 10.1016/j.isci.2021.102807 Source material
  2. [2] Bernkopf DB, Brückner M, Hadjihannas MV, et al. An aggregon in conductin/axin2 regulates Wnt/β-catenin signaling and holds potential for cancer therapy. Nature communications (2019). PMID: 31534175 DOI: 10.1038/s41467-019-12203-8 Source material
  3. [3] Fujita S, Mukai T, Mito T, et al. Pharmacological inhibition of tankyrase induces bone loss in mice by increasing osteoclastogenesis. Bone (2018). PMID: 29055830 DOI: 10.1016/j.bone.2017.10.017 Source material

Publications

1 publication citing this product

  1. Dominic B. Bernkopf, .et al. , Nat Commun, 2019, 10:4251 PMID: 31534175

Added to your cart

View Cart Checkout
Loading...